Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 07:19 AM
October 2025
Learn how to effectively manage Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction–Associated Steatohepatitis (MASH) through lifestyle interventions in this educational session presented by Tuesday Warner, NP, as part of the GHAPP MASLD Community Network. Using a real-world patient case, this session explores non-invasive testing (FIB-4, FibroScan), metabolic risk assessment, and the importance of personalized care strategies. Viewers will gain practical insights on optimizing diet, exercise, and behavioral modification—including calorie reduction, the Mediterranean diet, and sustainable weight loss—to improve liver outcomes and overall metabolic health.
#MASLD #MASH #MetabolicLiverDisease #LifestyleManagement #NonInvasiveTesting #FIB4 #FibroScan #WeightLoss #MediterraneanDiet #Obesity #Diabetes #InsulinResistance #Hepatology #GHAPP
Related Webcast
Webcast: MASLD vs MetALD With Sarah Dawkins
October 2025
In this session, Sarah Dawkins, NP, breaks down the overlap between MASLD and MetALD using a real case (FIB-4 = 2.01, FibroScan 11.4 kPa [F3], CAP 310). Presented via the GHAPP MASLD Community Network and supported by Madrigal Pharmaceuticals, she reviews how to stage disease with non-invasive tests (FIB-4, FibroScan/VCTE), why alcohol biomarkers (PEth) matter, and when to initiate HCC surveillance. Practical takeaways include counseling on a Mediterranean diet, exercise/weight loss targets, alcohol abstinence, and assessing candidacy for resmetirom in metabolic-predominant cases to slow fibrosis and improve outcomes.
Watch Now
Webcast: Non-Invasive Testing With Allison Moser
November 2025
In this educational session from the GHAPP MASLD Community Network, Allison Moser, NP, from Rush University Medical Center, explains how non-invasive testing (NITs) is changing the way clinicians assess and manage metabolic-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis (MASH). Through a real patient case study, she reviews key diagnostic tools like FIB-4, ELF, FibroScan, and MRI elastography, highlighting how each test helps identify fibrosis risk, reduce the need for biopsy, and guide patient management. Learn how to interpret test results, understand their limitations, and apply them in everyday clinical practice to improve liver health outcomes. #MASLD #MASH #Fibrosis #NonInvasiveTesting #FIB4 #ELFTest #FibroScan #MRIelastography #LiverHealth #Hepatology #APPeducation
Watch Now
Webcast: MASLD vs MetALD With Janet Gripshover
September 2025
Janet Gripshover, NP, explains how to spot and manage metabolic dysfunction–associated steatotic liver disease (MASLD) and MASH—now the preferred terms replacing NAFLD. Through a real patient case, she shows how ultrasound findings, everyday risk factors (PCOS, high blood pressure, cholesterol, higher BMI), and an honest alcohol history point the way. Janet covers easy, non-invasive tests (FIB-4 blood test, FibroScan® stiffness and CAP scores) and when alcohol biomarkers (PEth, urine EtG) help confirm what’s really driving the liver damage. You’ll learn simple next steps: Mediterranean-style eating, resistance exercise, weight loss goals, and complete alcohol cessation to prevent progression to cirrhosis. She also notes when to start liver cancer (HCC) screening and what to document in the chart. Perfect for APPs and clinicians looking for a clear, practical MASLD/MASH workflow.
Watch Now
Webcast: MASLD Basics With Anna Marie Hefner & Renee Pozza
October 2025
In this MASLD Community Network session, Anna Hefner, PhD, RN, CPNP, and Renee Pozza, PhD, RN, CNS, FNP-BC, of Southern California GI & Liver Centers break down the new nomenclature for steatotic liver disease (SLD) and what it means for clinical practice. They clarify how to distinguish MASLD from MASH, introduce the overlap category MetALD (metabolic-associated alcohol-related liver disease), and review differential causes of steatosis—from medications and viral hepatitis to genetic and cryptogenic etiologies. The faculty walk through practical primary-care screening with FIB-4, when to escalate with noninvasive tests (FibroScan® CAP/kPa, ELF), and the roles of ultrasound and MRI/MRE—plus when a liver biopsy is still warranted. You’ll learn staging cues (F0–F4), progression risk, who needs closer follow-up, and how to counsel patients on cardiometabolic risk reduction (weight loss, activity, triglyceride/HDL management, blood pressure, glucose). The talk also highlights pediatric considerations, terminology changes to reduce stigma, and tips for consistent waist-circumference measurement and alcohol-intake assessment—equipping PCPs, GI, and hepatology teams to identify fibrosis early and improve outcomes.
Watch Now
Webcast: MASLD Pharmacotherapy With Summer Collier
August 2025
Join Summer Collier, FNP, from UC San Diego Health, for a comprehensive discussion on pharmacotherapy for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and MASH, presented through the GHAPP MASLD/MASH Community Network and sponsored by Madrigal Pharmaceuticals. In this session, Summer outlines the foundational role of lifestyle modification in treating MASLD, including diet, exercise, and weight loss, while emphasizing the growing need for liver-directed therapies in patients with moderate to advanced fibrosis. She reviews the clinical use of GLP-1 receptor agonists such as semaglutide and tirzepatide, which aid in glycemic control and significant weight loss, and explores their application in hepatology—including key data showing MASH resolution and fibrosis improvement. The discussion also addresses older treatment options like vitamin E and pioglitazone, explaining their risks, limitations, and patient selection criteria. The highlight of the presentation is a detailed analysis of resmetirom (Rezdiffra)—the first FDA-approved therapy for non-cirrhotic NASH with F2–F3 fibrosis. Summer walks through the MAESTRO-NASH trial, covering the mechanism of THR-β activation, improvements in liver histology, safety data, and practical prescribing guidance, including non-invasive monitoring, statin dose considerations, and drug–drug interactions. The session concludes with expert insights on staging, treatment duration, insurance access, and the evolving future of MASLD therapy. A must-watch for hepatology, GI, and primary care providers seeking to implement the latest evidence-based approaches in managing fatty liver disease.
Watch Now
Live From GHAPP National: MASH: The Latest and Greatest of Management
November 2025
In this expert-led session, Allysa Saggese, NP, at Weill Cornell Medicine, breaks down the latest evidence and evolving best practices in the diagnosis and management of MASLD and MASH. She explains the 2023 nomenclature changes, the full spectrum of steatotic liver disease, and how metabolic dysfunction drives both MASLD and inflammatory MASH. Allysa reviews practical diagnostic pathways—including non-invasive tests like FIB-4, ELF, FibroScan, and elastography—and highlights why MASLD/MASH should always be evaluated in the broader context of metabolic disorders such as diabetes, obesity, and dyslipidemia. She also outlines the foundation of lifestyle-based treatment, offering real-world communication strategies to help patients succeed with diet, activity, and weight management goals. The talk covers major therapeutic advances, including the first FDA-approved MASH therapy, resmetirom (a THR-β agonist), as well as the growing role of GLP-1 receptor agonists like semaglutide in improving metabolic drivers of liver inflammation and fibrosis. Allysa discusses dosing, titration, safety considerations, expected side effects, and what clinicians should know when co-managing cardiometabolic conditions. She closes with insights on future MASH drug development, combination therapy approaches, and practical pearls for supporting patients through a chronic, complex liver disease.
Watch Now
Webcast: MASLD Pharmacotherapy With Elizabeth Goacher
September 2025
Elizabeth Goacher, PA-C from Duke Medical Center in Durham, NC, delivers an in-depth discussion on pharmacotherapy for MASLD/MASH, highlighting both current treatment options and emerging therapies. She reviews the role of GLP-1 receptor agonists in managing obesity and type 2 diabetes while offering secondary benefits for liver health, and addresses key considerations for procedural planning due to delayed gastric emptying. Elizabeth also explores the ongoing debate around vitamin E and pioglitazone, summarizing data from pivotal trials and guideline recommendations. The session emphasizes the groundbreaking approval of resmetirom, the first FDA-approved medication for MASH with F2–F3 fibrosis, detailing its mechanism as a thyroid hormone receptor beta agonist, trial outcomes, safety profile, and practical prescribing considerations, including payer coverage and drug interactions. This presentation provides hepatology and GI providers with practical insights on staging, non-invasive testing strategies (FIB-4, FibroScan, ELF, MRE), treatment sequencing, and how to integrate pharmacotherapy with lifestyle and multidisciplinary care to optimize outcomes in metabolic liver disease.
Watch Now
Webcast: Non-Invasive Testing With Tina Gregg
October 2025
In this session, Tina Gregg, NP-C, reviews non-invasive testing (NITs) for MASLD and MASH, using a real-world case to show how to assess risk and stage fibrosis without biopsy. Learn when to use FIB-4, ELF, FibroScan (VCTE), and MR elastography, how to interpret cutoffs, and when to refer to hepatology. Practical takeaways include triaging indeterminate FIB-4 results, recognizing test limitations, and counseling patients on lifestyle and follow-up. Presented via the GHAPP MASLD Community Network.
Watch Now
Webcast: MASLD Basics With Ann Moore
September 2025
In this episode of MASLD Basics, Ann Moore, NP with Arizona Liver Health, explains the new terminology and approach to what was once called fatty liver disease. She breaks down how “NAFLD” is being replaced with steatotic liver disease and how patients are now categorized based on underlying drivers such as metabolic dysfunction, alcohol use, or other conditions. Ann highlights why MASLD and MASH are the most common and important to recognize, what risk factors providers should look for, and why early detection matters. She also discusses how primary care teams can use simple non-invasive tests, lifestyle changes, and new treatment options to identify at-risk patients before fibrosis and cirrhosis develop. This talk is designed to give APPs, clinicians, and healthcare providers a clear, practical overview of the evolving landscape of liver disease care.
Watch Now
Webcast: MASLD vs MetALD With HoChong Gilles
November 2025
In this session from the GHAPP MASLD Community Network, supported by Madrigal Pharmaceuticals, hepatology expert HoChong Gilles, DNP, from the Richmond VA Medical Center, explores the evolving understanding of MetALD (Metabolic dysfunction-associated Alcohol-related Liver Disease). Through a detailed case study, Gilles examines how metabolic risk factors and alcohol intake intersect to drive fibrosis progression, highlighting diagnostic tools such as FibroScan, biomarkers like PEth, and key distinctions between MASLD, MASH, and alcohol-predominant liver disease. This presentation underscores the importance of assessing true alcohol exposure, utilizing noninvasive testing, and integrating lifestyle interventions for improved liver and metabolic outcomes.
Watch Now